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Background: Kawasaki disease is a multi-system vasculitis which usually occurs in children under 5 years of age. In
infants under three months of age, it is very rare and usually associated with a high incidence of incomplete or
atypical forms, often unresponsive to treatment. This condition increases the risk of cardiovascular complications
such as coronary artery aneurysms.
Case presentation: We describe a 3-month-old infant who developed early and severe aneurysms in three
coronary arteries despite a timely administration of intravenous immunoglobulins, followed by three days of
intravenous methylprednisolone.
Conclusion: This case report underlines that the development of coronary artery aneurysm correlates with a
delayed diagnosis and treatment, incomplete or atypical forms of the disease, and additionally the severity of
clinical presentation, especially in cases of very young infants below 3 months of age. Our case is notable because
of the very young age of the patient, the severity of clinical presentation with an early development of coronary
artery aneurysms and the unresponsiveness to the therapy.
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Kawasaki disease (KD) is an acute multisystem necrotizing
vasculitis of medium and small-size vessels of unknown eti-
ology [1], usually occurring in infants and children under 5
years [2,3]. KD was described for the first time in 1967 by
Tomisaku Kawasaki and it was named “mucocutaneous
lymph-node syndrome” [4]. Today it is known for its occur-
rence in small epidemics especially within closed communi-
ties and for its higher incidence in Asian populations [5].
The diagnosis of classic KD is based on the simultaneous
presence of high fever for 5 or more days with at least four
of the remaining five symptoms (bilateral conjunctival
hyperemia, ulcerations of the lips and inflammation of the
oral cavity, polymorphous rash, edema and desquamation
of the extremities and cervical lymphadenopathy) or fever
associated with less than 4 of the diagnostic criteria and
echocardiographic abnormalities of the coronary arteries.
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reproduction in any medium, provided the or30% of untreated children and may even lead to ischemic
heart disease, myocardial infarction (MI) or sudden death
[4,6].
In the acute phase, the aim of treatment is to reduce the
inflammation in the coronary artery wall and to prevent
coronary thrombosis whereas the long-term therapy, espe-
cially in patients with coronary ectasias or aneuryms, is to
prevent myocardial damage [6].
Presently, KD continues to be a disease with several prob-
lems [3]. The main difficulties for clinicians are how to per-
form a timely diagnosis, how to prevent cardiovascular
complications, and how to treat refractory forms. Refrac-
tory forms have been increasing markedly and both young
age of the patient and a delay in starting the treatment
seem to be major risk factors [7-9].
We describe a case of a 3-month-old male infant with
KD who developed severe coronary artery lesions despite
an early diagnosis and a timely administration of intra-
venous immunoglobulin (IVIG).al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Chest radiography. Generalized increased translucency of
the thorax. The heart size was within normal limits.
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A 3-month-old Caucasian male infant was admitted to
our department because of 24 hours of high-grade per-
sistent fever (T 39.5°C) not relieved by acetaminophen.
He was the second-born of non-consanguineous par-
ents, after 36 weeks gestation after an unremarkable
pregnancy. Birth weight was 3015 g. On admission, his
general condition was poor because of high fever
(T 39.5°C), tachycardia and tachypnea. On physical
examination, he presented with generalized edema and
non-palpable peripheral lymph-nodes. Muscle tone was
normal and lungs and heart examination was unremark-
able. Pharynx was hyperemic. Abdomen examination
was normal: liver and spleen were within normal limits.
Meningeal signs were absent but the patient was very ir-
ritable (Figure 1).
At the admission, laboratory test showed normocy-
tic anemia (hemoglobin 9 g/dL, red blood cells
3,180,000/mm3, mean corpuscular volume 80 fl),
neutrophilic leucocytosis (white blood cells 28,300/mm3,
neutrophils 69%) with a normal platelet count (200,000/
mm3). Laboratory investigations also showed elevated
gamma-glutamyltransferase (52 U/L), hyperbilirubinemia
(2.98 mg/dL), hypoalbuminemia (2.5 g/dL), hypopro-
teinemia (4.3 g/dL), hyponatremia (128 mEq/L); trans-
aminase levels were normal (aspartate aminotransfer-
ase 45 IU/L, alanine aminotransferase 40 IU/L).
C-reactive protein (CRP) confirmed the significant
state of inflammation (12.39 mg/dL).
Chest radiography showed a generalized increased
translucency of the thorax. The heart size was within
normal limits (Figure 2).
Abdominal ultrasound revealed slight hepatospleno-
megaly and mild peritoneal effusion.
Right coronary artery (RCA) on echocardiography re-
sulted to be within the maximum limits of normalityFigure 1 Patient’s face. Note fissures of the lips, inflammation of
the oral cavity and polymorphous rash.with mild hyperechogenicity of the wall. A small pericar-
dial effusion was detected too.
The patient was initially treated with intravenous anti-
biotic therapy (ceftriaxone) but, because of the persist-
ence of the fever we suspected KD, we started the first
dose of IVIG (2 g/kg in a single infusion) and replaced
acetaminophen with ibuprofen.
Nevertheless, the child continued to be febrile and a
generalized rash starting from the trunk and conjunctiv-
itis appeared. In addition, the hands and feet became
swollen (Figure 3).
Echocardiography examination performed after 48
hours from the first dose of IVIG showed a dilatation of
RCA (0.25 cm).
Due to the persistence of fever we performed a second
dose of IVIG.
After this treatment the patient developed fissuring of
the lips, hydrocele (Figure 4), ectasia of left coronary ar-
tery (LCA) and a worsening of the dilatation of RCA
(RCA: 0.45 cm; LCA: 0.32 cm) (Figure 5).
On the 10th day of illness, because of persistent fever, we
performed a bone marrow aspiration which showed no cel-
lular abnormalities and we started the administration of
intravenous methylprednisolone (IVMP, 30 mg/kg/day) for
3 consecutive days together with high-dose of acetylsalicylic
acid (80 mg/kg/day).
Although this treatment, laboratory tests showed
worsening of thrombocytosis (from 143,000/mm3 to
298,000/mm3), neutrophilic leukocytosis, anemia with
reticulocytosis, a further increase of CRP value and a
persistence of the fever.
Because of the marked increase of transaminase levels
(aspartate aminotransferase 230 IU/L, alanine amino-
transferase 427 IU/L), a week later, the dose of aspirin
was slightly reduced (60 mg/kg/day).
Figure 3 Patient’s limbs. Painful, brawny edema of the dorsa of the hand and foot.
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tinue steroid therapy by oral prednisone at dosage of
2 mg/kg/day and, after the improvement of the clin-
ical condition, we reduced the dosage at 1mg/kg/day
two weeks later.
Periungueal desquamation began on day fifteen and
lasted for a week (Figure 6). Although fever disappeared
19 days after onset of the illness and inflammatory in-
dexes turned into normal values, platelet count
remained high (Table 1) and for this reason we reduced
the dosage of acetylsalicylic acid at 5 mg/kg/day for its
anti-aggregant effects.
Finally, we used clopidogrel (1mg/Kg/day) instead of
acetylsalicylic acid at low dose for its anti-aggregant ef-
fects because of the persistence of the ectasia and the
dilatation of the coronary arteries (the maximum diame-
ters were 0.71 cm for RCA, 0.42 cm for LCA and 0.4 cm
for the left anterior descending artery - LAD).
Discussion
KD is commonly a self-limiting vasculitis although
coronary artery aneurysms may occur in approxi-
mately 25-30% of untreated patients. This complica-
tion represents the most important adverse prognostic
factor and it is the leading cause of death for
acquired heart disease in children [6,10]. Coronary
abnormalities occur more frequently during the sub-
acute phase of the disease and Harada [11] and BeiserFigure 4 Patient’s mouth and genitals. Fissuring of the lips and hydroce[12] scores represent the most predictive risk index to
identify this complication.
A timely diagnosis and an early beginning of treatment
represent a key clinical skill to prevent cardiac complica-
tions [13-15].
In our case, 6 days after the onset of fever we de-
tected an early alteration in the wall of both RCA
and LAD and during the following days an increase
in RCA diameter (0.41 cm).
Usually KD shows the highest incidence in children
under five years of age whereas is very rare under three
months of age (1.6%) [16,17].
The etiology of KD remains unknown, however a
combination of microbial infection and the immune
response or genetic susceptibility are believed to contrib-
ute to the development of KD, as has been suggested for
atopic diseases [18] and much attention has focused
on the role of a variety of genes related to inflammation
[19].
Moreover the clinical and epidemiological features
of KD also suggest that infectious agents might trig-
ger the development of this disease [20], although no
specific pathogens have been identified and significant
contribution of the innate immune system to the
pathophysiology of the acute phase of the disease has
been demonstrated in recent studies [21].
Six-month-old patients or younger often show in-
complete clinical features and this phenotype is linkedle.
Figure 5 Echocardiography. After second treatment with intravenous immunoglobulin the patient developed ectasia of left coronary artery and
a worsening of the dilatation of right coronary artery.
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[13,16,22-24].
According to standard therapy, 80-90% of treated
patients show a clinical and biochemical remission; in
the remaining percentage of patients a persistent
fever represents a sign of unresponsiveness to IVIG
which is the major risk factor for the development of
coronary artery lesions [7].
Kobayashi [7], Egami [8] and Sano [9] proposed
three different scoring systems in order to identify
the patients at high risk for unresponsiveness to ther-
apy with IVIG. According to these scores, in our pa-
tient the value resulted higher than the cut-off for
each one.
The use of IVMP and its efficacy in refractory forms is
still unclear. According to some authors, the use of IVMPFigure 6 Periungueal desquamation.seems to be associated with a decrease of fever. It remains
uncertain its role on the progression of coronary artery
anomalies although some other authors suggested a pre-
ventive role if IVMP is used during an early phase of the
disease [25-27].
Our patient’s clinical evolution seems to show that
before three months of age KD is associated with a
high risk of severe presentation and unresponsiveness
to therapy. In fact, in our patient an early diagnosis
and a timely starting of IVIG therapy was ineffective
in preventing coronary artery aneurysms.
The key to prevent this dangerous cardiac involve-
ment is still unknown although the resolution of sys-
temic inflammation as early as possible seems to
represent the target of the therapy [27]. In this re-
gard, in the absence of a standardized regime for re-
sistant forms with a high risk of development of
coronary artery anomalies, we suggest considering
IVMP associated with IVIG even during an early
phase of the disease if the score indexes are
predictive.
Furthermore since inflammatory and immunologic
processes of the innate immune system seem to have
a pivotal role in the development of KD even inflixi-
mab administration or plasma exchange can be very
important rescue methods for children refractory to
IVIG [28].Conclusion
Our case is notable because of the very young age of
the patient, the severity of clinical presentation with
an early development of coronary artery aneurysms
and the unresponsiveness to the therapy.















1 9 200,000 28,300 69 12.39
3 8.1 335,000 15,320 83 24 2.5 130
4 7.7 265,000 17,450 81 25 2.3
6 7.6 84,000 19,830 65 21 128
8 6.6 108,000 21,850 48 15.4 2.1 133
9 7.2 143,000 33,320 53 13.9
11 6.7 298,000 47,100 41 14.6 2.2
17 7.9 850,000 35,600 43 6.7 2.5
21 8.2 1,230,000 32,000 48 5.1 2.6
26 8.8 950,000 28,300 42 3.2 2.8
37 9.8 680,000 23,000 39 0.2 2.5
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